C12Y 301/03064
Phosphatidylinositol-3-phosphatase
Official title: Phosphatidylinositol-3-phosphatase (3.1.3.64)
C12Y301/03064 (Phosphatidylinositol-3-phosphatase) appears on 9 US grants and 12 published applications in this corpus.
Search patents in C12Y- Granted patents
- 9
- Published applications
- 12
- Assignees
- 12
- Inventors
- 20
- Latest grant
- 31 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 1 | 2 |
| 2016 | 2 | 0 |
| 2017 | 1 | 2 |
| 2018 | 1 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)31 Dec 2024US 12,178,856 B2Children's Medical Center Corporation
- Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)31 Jan 2023US 11,564,977 B2Children's Medical Center Corporation
- Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)11 Aug 2020US 10,736,945 B2Children's Medical Center Corporation
- Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)20 Feb 2018US 9,895,426 B2Children's Medical Center Corporation
- Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)12 Dec 2017US 9,839,677 B2Children's Medical Center Corporation
- Compositions and methods for the treatment of neuromuscular disorders8 Oct 2026US 2026/0308613 A1Astellas Gene Therapies, Inc.
- Compositions for treating xlmtm8 Jan 2026US 2026/0009049 A1Kate Therapeutics, Inc.
- Adeno-associated virus potency assay and uses thereof24 Jul 2025US 2025/0235560 A1Astellas Gene Therapies, Inc.
- Systemic gene replacement therapy for treatment of x-linked myotubular myopathy (xlmtm)3 Jun 2021US 2021/0162020 A1Children's Medical Center Corporation
- Mtmr2-s polypeptide for use in the treatment of myopathies9 Jul 2020US 2020/0215168 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides8US 8,834,866 B2Valerion Therapeutics, LLC · 2014
- Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)6US 8,957,044 B2Children's Medical Center Corporation · 2015
- Systemic gene replacement therapy for treatment of X-linked MyoTubular Myopathy (XLMTM)5US 9,415,120 B2Children's Medical Center Corporation · 2016
- Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides4US 9,447,394 B2Valerion Therapeutics, LLC · 2016
- Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)3US 9,839,677 B2Children's Medical Center Corporation · 2017